Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adeno-carcinoma: A single-center retrospective analysis.

Veröffentlicht vonbrigittemeiswinkel

Schlick, K; Gantschnigg, A; Seymer, A; Huemer, F; Greil, R; Weiss, L.

Cancer Med. 2023 Aug;12(16):16997-17004.  doi: 10.1002/cam4.6334. Epub 2023 Aug 3.

https://pubmed.ncbi.nlm.nih.gov/37537780/